Traditional methods of diagnosing Alzheimer’s rely heavily on subjective cognitive assessments and symptomatic evaluation, which frequently miss the early, preclinical stages of the disease. Fastball EEG, by contrast, operates on a principle of passivity: participants are only required to view a rapid sequence of images while their brain’s electrical responses are recorded. This approach bypasses the need for active memory recall or instruction following, thereby delivering an unbiased and sensitive measure of recognition memory function that is both scalable and accessible.

The research team published their findings in the respected journal Brain Communications, detailing the performance of this technique in various settings, including real-world environments such as participants’ own homes. This is a crucial advance, as most neurological diagnostics necessitate specialized clinical facilities and trained personnel, factors which limit widespread, early screening efforts. The ability to administer Fastball outside of hospital or laboratory settings heralds a democratization of dementia diagnosis, enabling earlier interventions and monitoring.

Fastball works by detecting characteristic neural responses known as event-related potentials (ERPs), which are elicited when the brain recognizes previously seen images within a rapid visual stream. The technique quantifies these electrical markers using electroencephalography (EEG), a non-invasive and cost-effective brain imaging modality with millisecond temporal resolution. The researchers demonstrated that diminished ERP signatures correspond strongly with early cognitive decline, even identifying subtle impairments in individuals who later progressed towards dementia.

This technological breakthrough arrives at a critical juncture in Alzheimer’s treatment landscape. Recently approved disease-modifying therapies such as donanemab and lecanemab have shown exceptional promise in slowing progression when administered during the early symptomatic phases of Alzheimer’s. However, these treatments’ maximal efficacy hinges on timely diagnosis— a challenge given that an estimated one in three people with dementia in England remain undiagnosed. Fastball EEG’s ability to facilitate early, objective detection could bridge this diagnostic gap, improving patient outcomes through prompt therapeutic intervention.

The study’s lead investigator, Dr. George Stothart, a cognitive neuroscientist specializing in memory neuroscience, highlighted the urgency of uncovering Alzheimer’s disease in its nascent stages. Conventional cognitive tests tend to detect memory decline only after substantial neurodegeneration has occurred. Fastball’s passive design, requiring minimal participant engagement, offers a radically new avenue for screening large populations efficiently and objectively, mitigating biases and variability inherent in subjective assessments.

Crucially, this research validates the reliability and robustness of the Fastball EEG protocol in diverse environments, showing consistent detection of memory impairment across both controlled laboratory conditions and everyday settings. This paves the way for its practical implementation in primary care facilities, memory clinics, and home-based health monitoring. The portable and user-friendly nature of the technology further facilitates large-scale deployment, potentially revolutionizing population screening for cognitive decline.

From a neuroscientific perspective, the Fastball test encapsulates cutting-edge application of cognitive electrophysiology in clinical diagnostics. By precisely capturing early-stage aberrations in recognition memory circuitry, it provides a window into the neural substrates affected by Alzheimer’s pathology. This objective probe into brain function stands in contrast to the limitations of neuroimaging techniques which, though informative, are costly and less scalable for widespread early detection.

The implications of this study extend beyond diagnosis; continuous and accessible monitoring of memory performance could shape the future landscape of personalized medicine for neurodegenerative disorders. Patients at risk could be tracked longitudinally with repeated Fastball assessments, enabling dynamic adjustment of therapeutic strategies and early detection of cognitive decline progression. Additionally, such tools may enhance recruitment and stratification in clinical trials aiming to test novel Alzheimer’s therapies.

Financially supported by the Academy of Medical Sciences and dementia charity BRACE, this research exemplifies successful collaboration between academia and charitable organizations dedicated to conquering dementia. BRACE’s ongoing investment underscores the transformative potential of Fastball EEG in expanding diagnostic capabilities and delivering equitable access to cognitive health assessments.

Leading voices in dementia research have praised this work as a crucial stepping stone toward overcoming the daunting challenge of underdiagnosis. By offering a low-cost, portable, and accurate diagnostic tool, Fastball EEG could catalyze a global shift in dementia care, reducing the burden on healthcare systems by enabling preemptive measures, early treatment, and more targeted support for affected individuals and their families.

Looking forward, the research team aims to refine the Fastball protocol further and expand studies to larger, more diverse populations. Integration with wearable EEG devices and machine learning algorithms for automated data interpretation could further enhance the scalability and precision of this early detection method. This innovation not only holds promise for Alzheimer’s but could be adapted for monitoring other neurodegenerative and cognitive disorders, broadening its impact on neurological health worldwide.

In sum, the University of Bath’s development of the Fastball test represents a transformative fusion of cognitive neuroscience, clinical research, and technological innovation. It addresses a critical unmet need for early, objective, and accessible detection of memory impairment associated with Alzheimer’s disease, with the potential to alter clinical practices and improve countless lives globally.

Subject of Research: People

Article Title: A passive and objective measure of recognition memory in mild cognitive impairment using Fastball memory assessment

News Publication Date: 1-Sep-2025

References:

1. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial, [DOI/link]
2. Lecanemab in Early Alzheimer’s Disease, [DOI/link]
3. Primary Care Dementia Data, NHS England [DOI/link]

Image Credits: Credit BRACE Dementia Research

Keywords: Alzheimer disease; Neurodegenerative diseases; Diseases and disorders; Neurological disorders; Health and medicine; Human health; Psychological science; Cognitive psychology; Cognition; Cognitive function; Mental images

Unlike traditional diagnostic methods that often rely on clinical evaluation or costly neuroimaging, the novel methodology exploits the subtle, intrinsic patterns hidden within the brain’s electrical activity. EEG, a non-invasive and relatively accessible modality, records neuronal oscillations that can reveal profound insights into brain function and dysfunction. Yet, EEG signals are inherently non-stationary and complex, requiring sophisticated algorithms to extract meaningful information. The study in question addresses these challenges by implementing two nonlinear mathematical techniques—Poincare and Entropy analyses—to uncover features that effectively discriminate among AD, MCI, and healthy individuals.

The Poincare method, rooted in nonlinear dynamics, provides a geometrical representation that captures variability and timing irregularities in physiological signals. When applied to EEG data, this technique offers a nuanced lens to observe the brain’s rhythmic fluctuations and adaptability. Complementing this, Entropy-based measures quantify the complexity and unpredictability of the EEG signals, yielding metrics that reflect the underlying neural informational richness or degradation. Together, these methodologies capture diverse facets of the EEG time series, presenting a comprehensive portrait of neural activity alterations associated with cognitive impairment.

A key strength of the study lies in its recognition of EEG’s non-stationary nature, which implies that the statistical properties of EEG signals change over time. To accommodate this, the researchers divided continuous EEG recordings into multiple short epochs, enabling detailed temporal analysis and feature extraction within these intervals. This epoch-based segmentation enhances the sensitivity of the derived features, providing machine learning algorithms with more robust and representative data inputs for classification purposes.

Once features were extracted, the data were fed into carefully selected machine learning classifiers trained to differentiate between Alzheimer’s disease, mild cognitive impairment, and cognitively healthy subjects. Machine learning offers a powerful framework to analyze complex, multidimensional datasets and identify patterns that may elude traditional statistical analyses. Through extensive experimental evaluation, the study verified that the combined use of Poincare and Entropy-derived features significantly improved classification performance, surpassing that of previous EEG-based diagnostic approaches.

Specifically, the researchers reported notable gains across key performance metrics, including accuracy, sensitivity, and specificity. Accuracy refers to the method’s overall ability to correctly identify individuals’ cognitive status, while sensitivity and specificity measure its proficiency in correctly detecting those with and without impairment, respectively. High sensitivity is particularly crucial in clinical screenings to minimize missed diagnoses, whereas high specificity reduces false positives that can cause undue anxiety and unnecessary follow-up procedures.

The implications of this research are profound. Early detection of Alzheimer’s and its precursor stages like MCI enables timely intervention, potentially slowing disease progression and maintaining quality of life. Additionally, the accessibility and cost-effectiveness of EEG-based diagnostics make this approach scalable for broader population screening, including in resource-limited settings where advanced neuroimaging is not feasible. The use of advanced nonlinear signal processing and machine learning collectively represents an emergent paradigm in neurodiagnostics, moving beyond surface-level analyses toward a mechanistic understanding of brain pathophysiology.

Critically, this study also opens new avenues for personalized medicine. By identifying subtle electrophysiological biomarkers unique to individual cognitive status, clinicians could monitor disease progression dynamically and tailor therapeutic strategies accordingly. Furthermore, the methodology’s adaptability suggests potential application to other neurological conditions characterized by disrupted brain rhythms, such as Parkinson’s disease or epilepsy, expanding its clinical relevance.

While promising, the research team acknowledges that further validation in larger, diverse populations is necessary to ensure broad applicability and reliability. Longitudinal studies could assess the predictive power of these EEG features over time, determining how early alterations manifest before clinical symptoms emerge. Integration with other biomarkers, such as neuropsychological tests or genetic information, could also enhance overall diagnostic accuracy.

Nevertheless, this pioneering work exemplifies how integrating cutting-edge mathematical methods with neuroscientific data can yield transformative healthcare solutions. As the global burden of neurodegenerative diseases escalates, innovations like these provide hope for more effective disease management through precision diagnostics. The convergence of biomedical engineering, data science, and neurology heralds a new era where invisible brain signals can be decoded to reveal vital truths about cognitive health.

In summary, by leveraging Poincare and Entropy analyses of EEG signals combined with machine learning, the researchers have established a powerful, non-invasive tool for differentiating Alzheimer’s, mild cognitive impairment, and healthy cognition with unprecedented accuracy. This breakthrough underscores the potential of nonlinear dynamics and complexity science to unlock the brain’s elusive signatures, paving the way for earlier interventions and improved patient outcomes in dementia care.

—

Subject of Research: Detection and classification of Alzheimer’s disease, mild cognitive impairment, and healthy cognition using nonlinear analysis of EEG signals.

Article Title: Detection of Alzheimer and mild cognitive impairment patients by Poincare and Entropy methods based on electroencephalography signals

Article References: Aslan, U., Akşahin, M.F. Detection of Alzheimer and mild cognitive impairment patients by Poincare and Entropy methods based on electroencephalography signals. BioMed Eng OnLine 24, 47 (2025). https://doi.org/10.1186/s12938-025-01369-6

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12938-025-01369-6